Uncontrolled Hypertension
Case study in CKD illustrates need for better communication between physicians, patients
FDA approves second renal denervation device to treat hypertension
The FDA approved a second renal denervation device to treat adults with uncontrolled hypertension despite an advisory panel’s vote regarding that system’s risks and benefits, Medtronic announced.
Intervention for uncontrolled hypertension also lowers dementia risk
PHILADELPHIA — A 48-month intervention to lower BP in patients with uncontrolled hypertension also reduced risk for dementia and cognitive impairment, according to data presented at the American Heart Association Scientific Sessions.
FDA approves first renal denervation device to treat hypertension
The FDA approved the first renal denervation device to treat adults with hypertension not adequately controlled with lifestyle changes and medications, ReCor Medical announced.
Post-hoc analysis supports association of BMI, reduced blood pressure with lorundrostat
PHILADELPHIA — Obesity-associated dysregulated aldosterone is an endotype predictive of response to lorundrostat for patients with uncontrolled or treatment-resistant hypertension, according to data presented at ASN Kidney Week.
New RADIANCE data: ‘Durable’ BP lowering, fewer meds after ultrasound renal denervation
SAN FRANCISCO — A new pooled analysis showed a maintained BP-lowering effect with fewer added medications after treatment with an ultrasound renal denervation system compared with a sham procedure, a speaker reported at TCT 2023.
Bilingual program improves BP in patients with previously uncontrolled hypertension
Remote BP monitoring and use of a bilingual phone app improved BP control among more than half of participants with initially uncontrolled hypertension, a speaker reported.
Self-measured BP control initiative lowers communities’ rates of uncontrolled hypertension
Additional training and technical assistance to improve self-measured BP in communities with high rates of uncontrolled hypertension successfully increased BP control from 2020 to 2022, a speaker reported.
Novel aldosterone synthase inhibitor safely lowers BP in uncontrolled hypertension
An investigational aldosterone synthase inhibitor was associated with clinically significant reductions in automated office BP for people with uncontrolled hypertension, with the greatest effects seen in people with concomitant obesity.
FDA panel says risks of radiofrequency renal denervation device outweigh benefits
A slim majority of FDA advisory panelists rejected that the benefits of a radiofrequency renal denervation system outweigh the risks for use in adults with uncontrolled hypertension despite use of antihypertensive medications.